VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DHR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DHRDanaher Corporation
$230.25$161.9B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
DHR logo

Danaher Corporation

DHR
NYSE · Life Science Tools
$230.25
At close - USD
Market Cap$161.86B
P/E45.7x
52W High$242.80
Volume3.74M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Bioprocessing Recovery Offsets Leverage And Goodwill Risks

Danaher's revenue growth inflected from -0.9% in 2025Q1 to 8.3% in 2026Q3 as bioprocessing destocking eased, with operating margin recovering to 19.0% from 16.5% in 2024Q3, suggesting the Life Sciences portfolio is normalizing though durability of end-demand w...

GrowthAccelerating
ProfitabilityModerate
ValuationAttractive
TechnicalsStrong
Explore valuation models
MARKET ACTION

DHR price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

11/12 Beats

EPS beat 11 of last 12 quarters

02

Valuation risk

+26% Peers

P/E is 26% above peer median

03

Market leadership

RS 85 · Leader

High momentum (Outperforming 85% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Jan 21
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue growth accelerated to 8.3% in 2026Q3 with gross margin at 58.5% and operating margin at 19.0%, indicating incomplete but genuine operating leverage as SG&A discipline offsets a rising $433M R&D line.

Analyst Consensus+3.7% target
Buy(43 analysts)
31 Buy11 Hold1 Sell

The Bull Case

Upside Catalysts

Life sciences leadership

Danaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through science and technology.

Bioprocessing recovery momentum

The company has shown strong bioprocessing recovery, contributing to a 14.14% stock price appreciation since previous coverage.

Conservative guidance upside

Management's conservative 2026 guidance sets a baseline that could be exceeded, with projected high-single-digit EPS growth and 3-6% core revenue growth.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
DHR+0.46%
S&P 500 (^GSPC)+7.63%
1-Year Return
DHR+10.02%
S&P 500 (^GSPC)+9.69%
3-Year Return
DHR+19.71%
S&P 500 (^GSPC)+71.31%
5-Year Return
DHR-11.70%
S&P 500 (^GSPC)+59.15%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
45.7x
Forward P/EExpansion
26.8x
EV/EBITDA40th %ile
23.2x
FCF YieldCash Flow
3.2%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
45.7x
36.3x
100th· High
EV/EBITDA
23.2x
23.3x
40th· Fair
Price/FCF
30.8x
30.4x
60th· Fair
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$108.00-53.1%
Base (Fair)$209.50-9.0%
Bull$329.30+43.0%
$108.00 Bear$209.50 Base$329.30 Bull
Current Market Price: $230.25
Trades at a 9.9% premium to Base DCF ($209.50)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue
$24.57B+2.9% YoY
Net income
$3.61B-7.3% YoY
Free cash flow
$5.26B-0.7% YoY
Operating margin
20.9%-0.8 pts YoY
ROIC (TTM)5.9%
Avg ROIC 5Y-
ROE (TTM)7.1%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate11/12 (92%)
Revenue Beat Rate9/12 (75%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 21, 2026
$2.11+9.9%
vs $1.92
$6.6B-0.1%
vs $6.6B
Q3 2026
Jul 21, 2026
$1.94+4.9%
vs $1.85
$6.3B+2.4%
vs $6.1B
Q2 2026
Apr 21, 2026
$2.06+6.2%
vs $1.94
$6.0B-0.5%
vs $6.0B
Q1 2026
Jan 28, 2026
$2.23+3.2%
vs $2.16
$6.8B+0.4%
vs $6.8B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

5 Stories
Zacks Investment Research·Oct 27, 2026
Danaher (DHR) Upgraded to Buy: Here's Why

Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Defense World·Oct 23, 2026
Danaher Corporation $DHR Shares Sold by Compass Wealth Management LLC

Compass Wealth Management LLC reduced its holdings in shares of Danaher Corporation (NYSE: DHR) by 9.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,242 shares of the conglomerate's stock after selling 4,464 shares during the period. Danaher comprises approximately 1.9%

Zacks Investment Research·Oct 22, 2026
LH vs. DHR: Which Stock Is the Better Value Option?

Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?

Seeking Alpha·Oct 22, 2026
Danaher Q3 Recap: Decent Results, Still A Hold

Danaher Corporation is rated hold, as the stock trades at a small premium and offers an 8.85% expected return, below my threshold. Q3 earnings showed solid performance: revenue up 8.3% YoY to $6.55B, adjusted EPS of $2.11, and strong segment growth, especially in Diagnostics. Key headwinds include respiratory revenue volatility and pricing pressure from China's volume-based procurement, despite some recent positive trends.

Filtered for Danaher CorporationMore Headlines
04

Compare before deciding

Benchmark DHR against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Danaher Corporation (DHR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
DHR logoDHRDanaher CorporationCurrent
$230.25$161.86B45.682.9%14.71%7.08%0.54%
TMO logoTMOThermo Fisher Scientific Inc.
$694.76$258.19B39.163.91%14.96%13.3%—
A logoAAgilent Technologies, Inc.
$174.76$49.36B38.246.73%19.53%20.47%—
WAT logoWATWaters Corporation
$457.60$34.22B42.536.99%1.75%0.81%—
BIO logoBIOBio-Rad Laboratories, Inc.
$381.57$10.27B13.690.65%8.59%3.15%—
BRKR logoBRKRBruker Corporation
$61.31$9.33B-408.732.08%-2.03%-2.87%—

Compare DHR vs Peers

Danaher Corporation (DHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs TMO

Most directly comparable listed peer for DHR.

Scale Benchmark

vs ABT

Larger-name benchmark to compare DHR against a more recognizable public peer.

Peer Set

Compare Top 5

vs TMO, A, WAT, BIO

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

DHR SEC Filings & Documents

Danaher Corporation (DHR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 21, 2026·SEC

Material company update

Oct 13, 2026·SEC

Material company update

Aug 3, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 20, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 21, 2026·SEC

FY 2026

Jul 21, 2026·SEC

FY 2026

Apr 21, 2026·SEC

Get notified when DHR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

DHR Frequently Asked Questions

Danaher Corporation (DHR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Danaher Corporation's revenue?

Danaher Corporation (DHR) reported $25.61B in revenue for fiscal year 2025. This represents a 1313% increase from $1.81B in 1996.

How fast is Danaher Corporation growing?

Danaher Corporation (DHR) grew revenue by 2.9% over the past year. Growth has been modest.

Is DHR profitable?

Yes, Danaher Corporation (DHR) is profitable, generating $4.33B in net income for fiscal year 2025 (14.7% net margin).

Dividend & Returns
Does DHR pay dividends?

Yes, Danaher Corporation (DHR) pays a dividend with a yield of 0.54%. This makes it attractive for income-focused investors.

What is DHR's return on equity?

Danaher Corporation (DHR) has a return on equity (ROE) of 7.1%. This is below average, suggesting room for improvement.

What is Danaher Corporation's free cash flow?

Danaher Corporation (DHR) generated $5.73B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in DHR back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →